ES2600554T3 - Prevención de la reducción del peso molecular del polímero, de la formación de impurezas y de la gelificación en composiciones poliméricas - Google Patents

Prevención de la reducción del peso molecular del polímero, de la formación de impurezas y de la gelificación en composiciones poliméricas Download PDF

Info

Publication number
ES2600554T3
ES2600554T3 ES04778698.3T ES04778698T ES2600554T3 ES 2600554 T3 ES2600554 T3 ES 2600554T3 ES 04778698 T ES04778698 T ES 04778698T ES 2600554 T3 ES2600554 T3 ES 2600554T3
Authority
ES
Spain
Prior art keywords
microspheres
acid
octreotide
rg503h
dcm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES04778698.3T
Other languages
English (en)
Spanish (es)
Inventor
B. C. Thanoo
James Murtagh
Gonto Johns
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oakwood Laboratories LLC
Original Assignee
Oakwood Laboratories LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oakwood Laboratories LLC filed Critical Oakwood Laboratories LLC
Application granted granted Critical
Publication of ES2600554T3 publication Critical patent/ES2600554T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
ES04778698.3T 2003-07-18 2004-07-19 Prevención de la reducción del peso molecular del polímero, de la formación de impurezas y de la gelificación en composiciones poliméricas Active ES2600554T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48857303P 2003-07-18 2003-07-18
US488573P 2003-07-18
PCT/US2004/023324 WO2005007122A2 (en) 2003-07-18 2004-07-19 Polymer stabilization

Publications (1)

Publication Number Publication Date
ES2600554T3 true ES2600554T3 (es) 2017-02-09

Family

ID=34079438

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04778698.3T Active ES2600554T3 (es) 2003-07-18 2004-07-19 Prevención de la reducción del peso molecular del polímero, de la formación de impurezas y de la gelificación en composiciones poliméricas

Country Status (7)

Country Link
US (3) US8343513B2 (ja)
EP (2) EP2462923A3 (ja)
JP (2) JP2008518881A (ja)
CA (3) CA2915574C (ja)
DK (1) DK1660039T3 (ja)
ES (1) ES2600554T3 (ja)
WO (1) WO2005007122A2 (ja)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008412B2 (en) * 2002-09-20 2011-08-30 Exxonmobil Chemical Patents Inc. Polymer production at supersolution conditions
ES2527286T3 (es) * 2004-04-30 2015-01-22 Abraxis Bioscience, Llc Microesferas de liberación sostenida y métodos de fabricación y uso de las mismas
CA2574085C (en) * 2004-07-16 2014-02-11 Oakwood Laboratories, L.L.C. Gonadotropin releasing hormone antagonists
US20090110744A1 (en) * 2005-03-01 2009-04-30 Sun Pharma Advanced Research Company Limited Sustained release pharmaceutical compositions
PT1968549E (pt) * 2005-12-22 2014-08-29 Novartis Ag Formulação de libertação controlada compreendendo octreotida e dois ou mais polímeros de polilactídeo-co-glicolídeo
WO2007084460A2 (en) * 2006-01-18 2007-07-26 Qps, Llc Pharmaceutical compositions with enhanced stability
KR100722607B1 (ko) * 2006-05-11 2007-05-28 주식회사 펩트론 분산성 및 주사 투여능이 향상된 서방성 미립구의 제조방법
NZ577281A (en) * 2006-12-18 2011-12-22 Takeda Pharmaceutical Sustained-release composition and method for producing the same
US8143352B2 (en) * 2006-12-20 2012-03-27 Exxonmobil Research And Engineering Company Process for fluid phase in-line blending of polymers
US8242237B2 (en) 2006-12-20 2012-08-14 Exxonmobil Chemical Patents Inc. Phase separator and monomer recycle for supercritical polymerization process
EP2160419B1 (en) * 2007-06-04 2013-11-13 ExxonMobil Chemical Patents Inc. Super-solution homogeneous propylene polymerization
CN101855249B (zh) * 2007-09-13 2013-02-13 埃克森美孚研究工程公司 在线生产增塑聚合物和增塑聚合物共混物的方法
US7910637B2 (en) * 2007-09-13 2011-03-22 Exxonmobil Research And Engineering Company In-line blending of plasticizers with a base polymer
CN103254497B (zh) * 2007-12-20 2015-11-18 埃克森美孚研究工程公司 生产聚丙烯和乙烯-丙烯共聚物的共混物的在线共混方法
US7910679B2 (en) * 2007-12-20 2011-03-22 Exxonmobil Research And Engineering Company Bulk homogeneous polymerization process for ethylene propylene copolymers
WO2009082463A1 (en) * 2007-12-20 2009-07-02 Exxonmobil Research And Engineering Company In-line process to produce pellet-stable polyolefins
US8318875B2 (en) * 2008-01-18 2012-11-27 Exxonmobil Chemical Patents Inc. Super-solution homogeneous propylene polymerization and polypropylenes made therefrom
KR101005562B1 (ko) * 2008-05-01 2011-01-05 한국생명공학연구원 난용성 약물을 함유하는 균일한 크기의 고분자 나노입자제조방법
GB0810990D0 (en) * 2008-06-16 2008-07-23 Q Chip Ltd Device and method of making solid beads
GB0814302D0 (en) 2008-08-05 2008-10-01 Coretherapix Slu Compounds and methods
US20100086597A1 (en) * 2008-10-06 2010-04-08 Oakwood Laboratories LLC Microspheres for the sustained release of octreotide with a low initial burst
US20100086596A1 (en) * 2008-10-06 2010-04-08 Oakwood Laboratories LLC Microspheres for releasing an octreotide compound without an initial time lag
CN102209531B (zh) * 2008-11-14 2014-08-27 梨花女子大学校产学协力团 高分子微球的制造方法和通过该方法制造的高分子微球
US20100143479A1 (en) * 2008-12-04 2010-06-10 Oakwood Laboratories, Llc Method of making sustained release microparticles
US20100266704A1 (en) * 2008-12-15 2010-10-21 Novartis Ag Octreotide depot formulation with constantly high exposure levels
WO2011087496A1 (en) * 2010-01-13 2011-07-21 Oakwood Laboratories LLC Microspheres for the sustained release of octreotide without an initial time lag
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
US10881605B2 (en) 2010-05-31 2021-01-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
LT2394663T (lt) 2010-05-31 2022-02-10 Laboratorios Farmaceuticos Rovi, S.A. Kompozicijos, skirtos įšvirkščiamiems in situ biologiškai skaidiems implantams
HUE029895T2 (en) * 2010-05-31 2017-04-28 Farm Rovi Lab Sa Antipsychotic injectable depot preparation
SI2529756T1 (sl) * 2011-05-31 2021-09-30 Laboratorios Farmaceuticos Rovi, S.A. Formulacija vsadka z risperidonom in/ali paliperidonom
PL2529757T3 (pl) * 2011-05-31 2014-04-30 Farm Rovi Lab Sa Formulacja implantu zawierającego paliperydon
MX2014010312A (es) * 2012-02-27 2015-04-14 Del Mar Pharmaceuticals Metodos analiticos mejorados para analizar y determinar impurezas en dianhidrogalactitol.
AU2013315118B2 (en) * 2012-09-17 2017-10-05 Pfizer Inc. Process for preparing therapeutic nanoparticles
AP2015008579A0 (en) * 2013-02-05 2015-07-31 Purdue Pharma Lp Tamper resistant pharmaceutical formulations
EP3071555A4 (en) * 2013-11-18 2017-05-31 Del Mar Pharmaceuticals Hplc analysis of impurities in dianhydrogalactitol
US20160106804A1 (en) * 2014-10-15 2016-04-21 Yuhua Li Pharmaceutical composition with improved stability
BR112018009644A2 (pt) 2015-11-12 2018-11-06 Graybug Vision Inc micropartículas agregantes sólidas modificadas na superfície, material injetável, processo para preparação de micropartículas agregantes sólidas modificadas na superfície, método para tratamento de um distúrbio ocular, e, uso de micropartículas agregantes sólidas modificadas na superfície
CN109414401B (zh) 2016-04-26 2023-06-13 阿代尔制药股份有限公司 用于胃肠外给药的生物可降解聚合物微球组合物
CN106822042A (zh) * 2017-01-24 2017-06-13 广州帝奇医药技术有限公司 一种利培酮缓释组合物及其制备方法
KR20190110567A (ko) * 2017-01-31 2019-09-30 베루 인코퍼레이티드 성선 자극 호르몬-방출 호르몬(GnRH) 길항제의 장기간 방출을 위한 조성물 및 방법
EP3727421A4 (en) 2017-12-18 2021-07-28 Foresee Pharmaceuticals Co., Ltd. PHARMACEUTICAL COMPOSITIONS WITH A CHOSEN DISCHARGE DURATION
CN111044731B (zh) * 2019-12-19 2021-05-07 北京科技大学 脉冲温育免疫反应分离富集多肽药物中肽类杂质的方法
JP2024507528A (ja) 2021-02-24 2024-02-20 オークウッド ラボラトリーズ，エル．エル．シー． ルラシドンを含むミクロスフェア製剤ならびにその製造方法および使用方法
BR112024002231A2 (pt) 2021-08-05 2024-04-30 Medincell S A Composição farmacêutica

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3755558A (en) 1971-02-23 1973-08-28 Du Pont Polylactide drug mixtures for topical application atelet aggregation
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
FR2537980B1 (fr) * 1982-12-17 1986-12-19 Sandoz Sa Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4818542A (en) 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
CA1236641A (en) 1984-07-06 1988-05-10 Motoaki Tanaka Copolymer of lactic acid and glycolic acid and method for producing same
DE3678308D1 (de) 1985-02-07 1991-05-02 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
ATE133087T1 (de) 1989-05-04 1996-02-15 Southern Res Inst Einkapselungsverfahren
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5478564A (en) 1990-02-22 1995-12-26 Teva Pharmaceutical Industries, Ltd. Preparation of microparticles for controlled release of water-soluble substances
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
JP3114245B2 (ja) * 1991-06-03 2000-12-04 藤沢薬品工業株式会社 持続性製剤の製造方法
WO1993003751A1 (en) * 1991-08-26 1993-03-04 Abbott Laboratories Compositions and methods for the sublingual or buccal administration of therapeutic agents
JP3277342B2 (ja) 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
US5480969A (en) 1992-09-15 1996-01-02 The Administrators Of The Tulane Educational Fund Antagonists of LHRH
US5656727A (en) 1992-09-15 1997-08-12 The Administrators Of The Tulane Educational Fund Antagonists of LHRH
JPH06150304A (ja) 1992-11-02 1994-05-31 Fuji Electric Co Ltd 磁気記録媒体およびその製造方法
CA2214889C (en) 1995-03-10 2005-05-24 Hans Koll Polypeptide-containing pharmaceutical forms of administration in the form of microparticles and a process for the production thereof
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
AU5678398A (en) 1997-01-29 1998-08-18 Takeda Chemical Industries Ltd. Sustained-release microspheres, their production and use
JPH10273447A (ja) * 1997-01-29 1998-10-13 Takeda Chem Ind Ltd 徐放性マイクロスフィア、その製造法および用途
US5945126A (en) 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
US6420518B1 (en) * 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6270802B1 (en) 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
KR100321854B1 (ko) * 1998-12-30 2002-08-28 동국제약 주식회사 루테이나이징 호르몬 릴리싱 호르몬 동족체를 함유하는 장기 서방출성 미립구 및 그의 제조방법
US6465425B1 (en) * 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
AU2001298061A1 (en) * 2000-12-13 2003-07-09 Purdue Research Foundation Microencapsulation of drugs by solvent exchange
CA2490351C (en) 2002-06-25 2011-11-01 Takeda Pharmaceutical Company Limited Process for producing sustained-release composition
US7164005B2 (en) * 2002-10-17 2007-01-16 Alkermes, Inc. Microencapsulation and sustained release of biologically active polypeptides
US7166575B2 (en) * 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
BRPI0412059A (pt) * 2003-07-15 2006-09-05 Pr Pharmaceuticals Inc método para a preparação de formulação de liberação controlada

Also Published As

Publication number Publication date
JP2011148812A (ja) 2011-08-04
US9017715B2 (en) 2015-04-28
US20050042294A1 (en) 2005-02-24
CA2819769A1 (en) 2005-01-27
CA2915574A1 (en) 2005-01-27
DK1660039T3 (en) 2017-01-16
EP1660039B1 (en) 2016-09-28
US20160310601A1 (en) 2016-10-27
EP2462923A3 (en) 2012-08-29
JP2008518881A (ja) 2008-06-05
EP1660039A2 (en) 2006-05-31
US8343513B2 (en) 2013-01-01
CA2533314C (en) 2013-07-09
EP2462923A2 (en) 2012-06-13
WO2005007122A3 (en) 2005-09-09
CA2915574C (en) 2017-02-07
US20130165377A1 (en) 2013-06-27
EP1660039A4 (en) 2009-08-12
CA2533314A1 (en) 2005-01-27
US10561734B2 (en) 2020-02-18
CA2819769C (en) 2016-06-28
WO2005007122A2 (en) 2005-01-27

Similar Documents

Publication Publication Date Title
ES2600554T3 (es) Prevención de la reducción del peso molecular del polímero, de la formación de impurezas y de la gelificación en composiciones poliméricas
KR100293882B1 (ko) 카르복시말단폴리에스테르와펩티드와의염
CN101035512B (zh) 用于生物活性化合物可控制释放递送的药物组合物
KR101224004B1 (ko) 단백질, 폴리펩타이드 또는 펩타이드 약물 전달용 고분자 및 그 제조방법, 및 단백질, 폴리펩타이드 또는 펩타이드 약물의 서방형 조성물 및 그 제조 방법
JP4187789B2 (ja) ポリ（エーテル−エステル）ブロックポリマーを基剤とする感熱生分解性ポリマー
Jordan et al. Sustained release hGH microsphere formulation produced by a novel supercritical fluid technology: in vivo studies
KR101626632B1 (ko) 제약 조성물
EP1028746B1 (en) Method for producing igf-i sustained-release formulations
KR20010030889A (ko) 가역적 열 겔화 성질을 갖는 생분해성 저분자량 트리블럭폴리(락티드-코-글리콜리드) 폴리에틸렌 글리콜 공중합체
JP2011144207A (ja) 制御放出処方物の調製のための方法
KR101467275B1 (ko) 분산성이 향상된 생분해성 고분자 미립자의 조성물 및 그 제조방법
CN103269689A (zh) 含有生理活性肽的微粒及其制备方法和包括该微粒的药物组合物
KR100838219B1 (ko) 인간성장호르몬의 지속적인 방출이 가능한 생분해성약학적 조성물 및 미립구 제형